NCT03321110

Brief Summary

The aims of the study are 1) to compare the differences in plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances in athletes (i.e., soccer, and taekwondo players) and healthy non-athletes; 2) to investigate the relationship between plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances; 3) to explore the influence on plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances after 12 weeks of coenzyme Q10 intervention (150 mg/day and 300 mg/day).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
43

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 13, 2017

Completed
12 days until next milestone

First Posted

Study publicly available on registry

October 25, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

December 1, 2017

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2019

Completed
Last Updated

March 23, 2020

Status Verified

March 1, 2020

Enrollment Period

1.7 years

First QC Date

October 13, 2017

Last Update Submit

March 19, 2020

Conditions

Athlete

Outcome Measures

Primary Outcomes (1)

  • malondialdehyde (MDA)

    MDA (micromol/L) will measure by thiobarbituric acid reacting substance.

    12 weeks

Secondary Outcomes (8)

  • Antioxidant capacity

    12 weeks

  • high sensitivity C-reactive protein (hs-CRP)

    12 weeks

  • creatine kinase (CK)

    12 weeks

  • Lactate dehydrogenase (LDH)

    12 weeks

  • one-repetition maximum (1-RM)

    12 weeks

  • +3 more secondary outcomes

Study Arms (3)

Placebo

EXPERIMENTAL

Placebo

Other: Placebo

Q10-150

EXPERIMENTAL

coenzyme Q10 150 mg/d.

Dietary Supplement: Coenzyme Q10

Q10-300

EXPERIMENTAL

coenzyme Q10 300 mg/d.

Dietary Supplement: Coenzyme Q10

Interventions

PlaceboOTHER

Placebo (dextrin)

Placebo
Coenzyme Q10DIETARY_SUPPLEMENT

150 mg or 300 mg

Q10-150Q10-300

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Athletes (soccer and taekwondo players)

You may not qualify if:

  • Antioxidant vitamins users
  • Statins or Aspirin therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chung Shan Medical University

Taichung, 40201, Taiwan

Location

MeSH Terms

Interventions

coenzyme Q10

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: placebo-control
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 13, 2017

First Posted

October 25, 2017

Study Start

December 1, 2017

Primary Completion

July 31, 2019

Study Completion

July 31, 2019

Last Updated

March 23, 2020

Record last verified: 2020-03

Data Sharing

IPD Sharing
Will not share

Locations

TW(1)